Continuing GLP-1 receptor agonist medications when undergoing an endoscopic procedure appeared safe in a meta-analysis.

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...

Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...

Joseph Sanchez, MD, a general surgery resident at Northwestern Medicine, Chicago, and colleagues conducted a ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Hanmi Pharm. Co., Ltd. has announced promising research results for its novel obesity treatment, HM17321. This groundbreaking ...

0001). Of note, hormonal therapy was associated with a lower risk for AKI (OR,.645; P < .0001). Again, GLP-1 use wasn’t significantly associated with a risk for AKI (OR, 1.138; P = .2568).

For patients with opioid use disorder (OUD) and alcohol use disorder (AUD), prescriptions of glucose-dependent insulinotropic polypeptide (GIP) and/or glucagon-like peptide-1 receptor agonists (GLP-1 ...

Most patients may continue to safely take glucagon-like peptide-1 (GLP-1) receptor agonists as prescribed before undergoing ...